JP2015178480A - 骨減少性疾患改善剤およびびわ抽出物製造方法 - Google Patents
骨減少性疾患改善剤およびびわ抽出物製造方法 Download PDFInfo
- Publication number
- JP2015178480A JP2015178480A JP2014057299A JP2014057299A JP2015178480A JP 2015178480 A JP2015178480 A JP 2015178480A JP 2014057299 A JP2014057299 A JP 2014057299A JP 2014057299 A JP2014057299 A JP 2014057299A JP 2015178480 A JP2015178480 A JP 2015178480A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- extract
- methyl
- compound
- loquat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000009008 Eriobotrya japonica Nutrition 0.000 title claims abstract description 25
- 241001092070 Eriobotrya Species 0.000 title claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 208000029725 Metabolic bone disease Diseases 0.000 title abstract description 3
- 206010049088 Osteopenia Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940096998 ursolic acid Drugs 0.000 claims abstract description 5
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims abstract description 5
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims abstract description 4
- FRWNAQDBODEVAL-VMPITWQZSA-N (5e)-5-[(4-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\1C(=O)NC(=S)S/1 FRWNAQDBODEVAL-VMPITWQZSA-N 0.000 claims abstract description 4
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 claims abstract description 4
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 claims abstract description 4
- ZZTYPLSBNNGEIS-OPAXANQDSA-N Pomolic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C ZZTYPLSBNNGEIS-OPAXANQDSA-N 0.000 claims abstract description 3
- JYEJQUHSBMDABO-SYKQLJDKSA-N Pomolic acid Natural products C[C@@H]1CC[C@@]2(CC[C@H]3[C@@H]4CC[C@H]5C(C)(C)[C@@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2[C@]1(C)O)C(=O)O JYEJQUHSBMDABO-SYKQLJDKSA-N 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- BZORLJPADUHVJE-UHFFFAOYSA-N 3-O-cis-p-coumaroyltormentic acid Natural products C12C(O)(C)C(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CC(O)C4OC(=O)C=CC1=CC=C(O)C=C1 BZORLJPADUHVJE-UHFFFAOYSA-N 0.000 claims description 7
- XKVJDMFZIZPEDG-UHFFFAOYSA-N 3-O-trans-p-coumaroyltormentic acid Natural products CC1CCC2(CCC3(C)C(CCC4C5(C)CC(O)C(OC(=O)C=Cc6ccc(O)cc6)C(C)(C)C5CCC34C)C2C1(C)O)C(=O)O XKVJDMFZIZPEDG-UHFFFAOYSA-N 0.000 claims description 7
- HFGSQOYIOKBQOW-RFMFWNHYSA-N (1s,2r,4as,6ar,6as,6br,8ar,10s,11r,12ar,14bs)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid Chemical compound C1[C@@H](O)[C@@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C HFGSQOYIOKBQOW-RFMFWNHYSA-N 0.000 claims description 6
- -1 methyl corosolic acid Chemical compound 0.000 claims description 5
- RIXNFYQZWDGQAE-DFHVBEEKSA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C([C@H]1C2=CC[C@H]34)C(C)(C)CC[C@]1(C(O)=O)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C RIXNFYQZWDGQAE-DFHVBEEKSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- VWHRYODZTDMVSS-UHFFFAOYSA-N 2-azaniumyl-3-(3-fluorophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=CC(F)=C1 VWHRYODZTDMVSS-UHFFFAOYSA-N 0.000 claims description 2
- BZORLJPADUHVJE-AHJFQOKESA-N (1r,2r,4as,6ar,6as,6br,8ar,10r,11r,12ar,14bs)-1,11-dihydroxy-10-[(z)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@H]1[C@H](O)C[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CC[C@H]([C@@]([C@H]14)(C)O)C)C(O)=O)C(=O)\C=C/C1=CC=C(O)C=C1 BZORLJPADUHVJE-AHJFQOKESA-N 0.000 claims 2
- BZORLJPADUHVJE-QWBBESJSSA-N 3-O-trans-p-coumaroyltormentic acid Chemical compound O([C@H]1[C@H](O)C[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CC[C@H]([C@@]([C@H]14)(C)O)C)C(O)=O)C(=O)\C=C\C1=CC=C(O)C=C1 BZORLJPADUHVJE-QWBBESJSSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000003523 triterpene group Chemical group 0.000 claims 1
- 125000002220 ursolic acid group Chemical group 0.000 claims 1
- 210000002997 osteoclast Anatomy 0.000 abstract description 25
- 230000004069 differentiation Effects 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 150000003648 triterpenes Chemical class 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 6
- OXVUXGFZHDKYLS-BLIWDXROSA-N Tormentic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-BLIWDXROSA-N 0.000 abstract description 4
- VULLSLYDWNGNKZ-UHFFFAOYSA-N 12319Tetrahydroxyurs-12-en-28-oic acid Natural products OC1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C VULLSLYDWNGNKZ-UHFFFAOYSA-N 0.000 abstract description 2
- OTDUGESKRJHFHR-UHFFFAOYSA-N 2alpha-Hydroxyoleanolsaeuremethylester Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C OTDUGESKRJHFHR-UHFFFAOYSA-N 0.000 abstract description 2
- 229930182603 Euscaphic acid Natural products 0.000 abstract description 2
- OXVUXGFZHDKYLS-UHFFFAOYSA-N Jacarandic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C OXVUXGFZHDKYLS-UHFFFAOYSA-N 0.000 abstract description 2
- BRZWXKGDPAZBLF-UHFFFAOYSA-N UNPD45812 Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)CCC3(C(=O)OC)CCC21C BRZWXKGDPAZBLF-UHFFFAOYSA-N 0.000 abstract description 2
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- OXVUXGFZHDKYLS-QUFHAEKXSA-N euscaphic acid Chemical compound C1[C@@H](O)[C@@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-QUFHAEKXSA-N 0.000 abstract description 2
- BRZWXKGDPAZBLF-OKUTUCSLSA-N methyl (1s,2r,4as,6ar,6as,6br,8ar,10r,11r,12ar,14bs)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1h-picene-4a-carboxylate Chemical compound C([C@@]12C)[C@@H](O)[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3[C@@H](C)[C@H](C)CC[C@]3(C(=O)OC)CC[C@]21C BRZWXKGDPAZBLF-OKUTUCSLSA-N 0.000 abstract description 2
- OTDUGESKRJHFHR-SUXCAEKLSA-N methyl (4as,6ar,6as,6br,8ar,10r,11r,12ar,14bs)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate Chemical compound C([C@@]12C)[C@@H](O)[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C OTDUGESKRJHFHR-SUXCAEKLSA-N 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 description 6
- 230000024279 bone resorption Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 244000061508 Eriobotrya japonica Species 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 3
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- YFLYOZWZPSYMPX-DCLYBNOZSA-N (3as,5ar,5bs,7as,10r,11r,11as,13as,13bs)-11-hydroxy-1-(hydroxymethyl)-3,3,5a,5b,10,11,13b-heptamethyl-4,5,6,7,8,9,10,11a,13,13a-decahydro-3ah-cyclopenta[a]chrysene-7a-carboxylic acid Chemical compound C1C[C@@]2(C)[C@]3(C)CC[C@@]4(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]4C3=CC[C@@H]2[C@@]2(C)C(CO)=CC(C)(C)[C@H]12 YFLYOZWZPSYMPX-DCLYBNOZSA-N 0.000 description 2
- LJORXTIGOHMBOS-UHFFFAOYSA-N 2alpha,19alpha-Dihydroxy-3-oxo-12-ursen-28-oic acid Natural products C1C(O)C(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C LJORXTIGOHMBOS-UHFFFAOYSA-N 0.000 description 2
- LJORXTIGOHMBOS-OTRVPSFMSA-N 2alpha,19alpha-dihydroxy-3-oxo-12-ursen-28-oic acid Chemical compound C1[C@@H](O)C(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C LJORXTIGOHMBOS-OTRVPSFMSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- TWTJCGZZSCXJRN-SBJHNJPWSA-N hyptadienic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4C5=C(CO)CC(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@]1(C)O)C(=O)O TWTJCGZZSCXJRN-SBJHNJPWSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GGSURCIXQQGITI-UHFFFAOYSA-N methyl pentacosa-10,12-diynoate Chemical compound CCCCCCCCCCCCC#CC#CCCCCCCCCC(=O)OC GGSURCIXQQGITI-UHFFFAOYSA-N 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- XUARCIYIVXVTAE-ZAPOICBTSA-N uvaol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C XUARCIYIVXVTAE-ZAPOICBTSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 102100036506 11-beta-hydroxysteroid dehydrogenase 1 Human genes 0.000 description 1
- 101710186107 11-beta-hydroxysteroid dehydrogenase 1 Proteins 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- MUCRYNWJQNHDJH-UHFFFAOYSA-N Ursonic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(C)C5C4=CCC3C21C MUCRYNWJQNHDJH-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 150000003675 ursolic acids Chemical class 0.000 description 1
- SYFNOXYZEIYOSE-UHFFFAOYSA-N uvaol Natural products CC1CCC2(O)CCC3(C)C(=CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C SYFNOXYZEIYOSE-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (3)
- びわ葉から抽出されるびわ抽出物を製造するびわ抽出物製造方法において、
中間抽出物を抽出する中間工程と、
前記中間抽出物から、3-エピコロソリック酸、6b,19-ジヒドロキシ-3-オキソウルス-12-エン-28-オイック酸、ウルソール酸メチルエステルおよびアセチルオレアノール酸、からなる群から選択される化合物のうち少なくとも1つの濃度を低減させる工程と、
を含むびわ抽出物製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014057299A JP2015178480A (ja) | 2014-03-19 | 2014-03-19 | 骨減少性疾患改善剤およびびわ抽出物製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014057299A JP2015178480A (ja) | 2014-03-19 | 2014-03-19 | 骨減少性疾患改善剤およびびわ抽出物製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2015178480A true JP2015178480A (ja) | 2015-10-08 |
Family
ID=54262814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014057299A Pending JP2015178480A (ja) | 2014-03-19 | 2014-03-19 | 骨減少性疾患改善剤およびびわ抽出物製造方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2015178480A (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017210443A (ja) * | 2016-05-26 | 2017-11-30 | 公益財団法人東洋食品研究所 | トリテルペノイドの抽出方法、および、トリテルペノイドおよびカロテノイドを分離する方法 |
WO2018066704A1 (ja) * | 2016-10-07 | 2018-04-12 | 国立大学法人 九州大学 | メラニン抑制剤、抗菌剤、抗アレルギー剤、コラーゲン生成促成剤および保湿剤 |
WO2018079715A1 (ja) * | 2016-10-27 | 2018-05-03 | サントリーホールディングス株式会社 | Foxo1活性阻害用組成物 |
WO2020161221A1 (en) | 2019-02-07 | 2020-08-13 | Luxembourg Institute Of Science And Technology (List) | METHOD FOR PRODUCING A COMPOSITION COMPRISING A 3-O-p-COUMAROYL ESTER OF TORMENTIC ACID FROM A PLANT CELL CULTURE, APPLICATIONS THEREOF AS ANTIPARASITIC AGENT FOR THE TREATMENT OF TRYPANOSOMIASIS |
CN112300241A (zh) * | 2020-11-03 | 2021-02-02 | 浙江工业大学 | 一种枇杷叶中分离制备科罗索酸和山楂酸的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014141444A (ja) * | 2012-12-27 | 2014-08-07 | Nippon Flour Mills Co Ltd | トリテルペン類を有効成分とする骨粗鬆症予防剤 |
-
2014
- 2014-03-19 JP JP2014057299A patent/JP2015178480A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014141444A (ja) * | 2012-12-27 | 2014-08-07 | Nippon Flour Mills Co Ltd | トリテルペン類を有効成分とする骨粗鬆症予防剤 |
Non-Patent Citations (2)
Title |
---|
"Inhibitory Effects of the Leaves of Loquat (Eriobotrya japonica) on Bone Mineral Density Loss in Ova", J. AGRIC. FOOD CHEM., vol. 62, no. 4, JPN6018000087, 29 January 2014 (2014-01-29), pages 836 - 841, ISSN: 0003902575 * |
"Maslinic Acid Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Regulating", J. BONE MINERAL RES., vol. 26, no. 3, JPN7016001761, 2011, pages 644 - 656, ISSN: 0003902576 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017210443A (ja) * | 2016-05-26 | 2017-11-30 | 公益財団法人東洋食品研究所 | トリテルペノイドの抽出方法、および、トリテルペノイドおよびカロテノイドを分離する方法 |
WO2018066704A1 (ja) * | 2016-10-07 | 2018-04-12 | 国立大学法人 九州大学 | メラニン抑制剤、抗菌剤、抗アレルギー剤、コラーゲン生成促成剤および保湿剤 |
WO2018079715A1 (ja) * | 2016-10-27 | 2018-05-03 | サントリーホールディングス株式会社 | Foxo1活性阻害用組成物 |
JP2022130618A (ja) * | 2016-10-27 | 2022-09-06 | サントリーホールディングス株式会社 | Foxo1活性阻害用組成物 |
WO2020161221A1 (en) | 2019-02-07 | 2020-08-13 | Luxembourg Institute Of Science And Technology (List) | METHOD FOR PRODUCING A COMPOSITION COMPRISING A 3-O-p-COUMAROYL ESTER OF TORMENTIC ACID FROM A PLANT CELL CULTURE, APPLICATIONS THEREOF AS ANTIPARASITIC AGENT FOR THE TREATMENT OF TRYPANOSOMIASIS |
CN112300241A (zh) * | 2020-11-03 | 2021-02-02 | 浙江工业大学 | 一种枇杷叶中分离制备科罗索酸和山楂酸的方法 |
CN112300241B (zh) * | 2020-11-03 | 2021-12-21 | 浙江工业大学 | 一种枇杷叶中分离制备科罗索酸和山楂酸的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015178480A (ja) | 骨減少性疾患改善剤およびびわ抽出物製造方法 | |
Wang et al. | Ursolic acid attenuates lipopolysaccharide-induced cognitive deficits in mouse brain through suppressing p38/NF-κB mediated inflammatory pathways | |
CN103788108B (zh) | 氧杂双环庚烷和氧杂双环庚烯,它们的制备及用途 | |
Song et al. | α-linolenic acid inhibits receptor activator of NF-κB ligand induced (RANKL-induced) Osteoclastogenesis and prevents inflammatory bone loss via downregulation of nuclear factor-KappaB-inducible nitric oxide synthases (NF-κB-iNOS) signaling pathways | |
WO2014022772A1 (en) | Tomatidine, analogs thereof, compositions comprising same, and uses for same | |
CN104203901A (zh) | 治疗炎症的组合物和方法 | |
Tsepaeva et al. | Synthesis, anticancer, and antibacterial activity of betulinic and betulonic acid C-28-triphenylphosphonium conjugates with variable alkyl linker length | |
JP2012526806A (ja) | リコピンおよびレスベラトロールの栄養補助食品 | |
Mohanraj et al. | The mycobacterial adjuvant analogue TDB attenuates neuroinflammation via Mincle-independent PLC-γ1/PKC/ERK signaling and microglial polarization | |
JP2015527360A5 (ja) | ||
RU2012136826A (ru) | Терапевтическое или профилактическое средство для заболеваний желчных путей | |
EP3053581A1 (en) | Therapeutic agent for osteoporosis | |
Fernandes et al. | Chalcone T4, a novel chalconic compound, inhibits inflammatory bone resorption in vivo and suppresses osteoclastogenesis in vitro | |
CN109963594A (zh) | 治疗皮肤病症的包含噻唑和开环甾类化合物的组合疗法 | |
WO2017127272A1 (en) | Beneficial effect of bidens pilosa on fat decrease and muscle increase | |
JPWO2004035089A1 (ja) | ホルモン依存性癌の治療剤 | |
CN104188977A (zh) | 闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物在制备抗骨质酥松药物中的应用 | |
RU2715679C1 (ru) | Способ снижения прооксидантного действия антиконвульсантов в эксперименте | |
JP2010090097A (ja) | 抗骨粗鬆症組成物 | |
CN104013611A (zh) | 芒果苷元及衍生物在制备抗前列腺增生药物中的应用 | |
Yao et al. | Zhi Zhou, Wenkai Jiang, Junjie Yan, Hedong Liu, Maoxian Ren, Yang Li, Zhiyi Liu | |
EP3038655A2 (en) | Method and products for enhancing cellular uptake of drug and dietary supplements | |
CN109453397A (zh) | 一种黄姜顺磁共振组合剂 | |
Park et al. | Plant-derived Omega-3 Fatty Acids Have Anti-carcinogenic Effect in MCF-7 Breast Cancer Cells | |
CN103006570B (zh) | 一种阿佐昔芬速释微丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170318 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170318 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170620 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180306 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180823 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180827 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20181019 |